Literature DB >> 6788788

Assay of alpha-difluoromethylornithine in body fluids and tissues by automatic amino-acid analysis.

J Grove, J R Fozard, P S Mamont.   

Abstract

A procedure is described for the measurement of DL-alpha-difluoromethylornithine (DFMO), a selective irreversible inhibitor of ornithine decarboxylase, in biological specimens. The drug is separated from other amino acids with a commerical amino-acid analyser and detected by formation of its alkylthio-isoindole derivative with o-phthalaldehyde. DFMO concentrations of 0.1 nmol can be determined in a sample volume of 100 microliter. The assay has been used to determine the half-life of DFMO in serum of several species and the relationships between serum and tissue concentrations.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6788788     DOI： 10.1016/s0378-4347(00)80114-0

Source DB:  PubMed          Journal:  J Chromatogr


  18 in total

Review 1.  Recent advances in the biochemistry of polyamines in eukaryotes.

Authors:  A E Pegg
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

2.  Legionella pneumophila requires polyamines for optimal intracellular growth.

Authors:  Gheyath K Nasrallah; Angela L Riveroll; Audrey Chong; Lois E Murray; P Jeffrey Lewis; Rafael A Garduño
Journal:  J Bacteriol       Date:  2011-07-08       Impact factor: 3.490

3.  Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.

Authors:  K Chin; S Merali; M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.

Authors:  C A Griffin; M Slavik; S C Chien; J Hermann; G Thompson; O Blanc; G D Luk; S B Baylin; M D Abeloff
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

5.  Autoradiographic localization of ornithine decarboxylase in mouse kidney by use of radiolabeled alpha-difluoromethylornithine.

Authors:  I S Zagon; P J McLaughlin; J E Seely; G W Hoeksema; A E Pegg
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

6.  CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs.

Authors:  V A Levin; D Byrd; J Campbell; R L Davis; J K Borcich
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness.

Authors:  K Na-Bangchang; F Doua; J Konsil; W Hanpitakpong; B Kamanikom; F Kuzoe
Journal:  Eur J Clin Pharmacol       Date:  2004-05-13       Impact factor: 2.953

8.  Effects of alpha-difluoromethylornithine on initiation and promotion of urinary bladder carcinogenesis in a heterotopically transplanted rat urinary bladder.

Authors:  K Rinsho; K Uchida; S Samma; R Oyasu
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 9.  A perspective of polyamine metabolism.

Authors:  Heather M Wallace; Alison V Fraser; Alun Hughes
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

10.  Effects of DL-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumour induced by 7,12-dimethylbenz[a]anthracene.

Authors:  J R Fozard; N J Prakash
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.